Diabetes
Conditions
Keywords
Advanced hybrid closed loop, pediatrics, real-world, time in range
Brief summary
Hybrid closed-loop technology have shown that it improves glycemic control parameters, but the investigators do not have sufficient data at more than 6 months of follow-up, allowing us to describe the effectiveness of these systems in the long term. All MiniMed 780G system users from November 2020 to March 2022 were included (n=32) For every time points, there was a significant difference in Time In Range between the pre-AHCL and post-AHCL. Noted difference were +14.5% and, +10.8% at respectively 3 months and 1 year. No more hypoglycemia were identified. This real-life analysis shows that the algorithm is effective in improvement of metabolic control for T1 diabetic children and adolescents, at one year of follow-up. However, an effect of breathlessness is observed which underlined the need for a solid therapeutic education program.
Interventions
None listed
Sponsors
University Hospital, Montpellier
Study design
Observational model
COHORT
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
No minimum to 18 Years
Healthy volunteers
No
Inclusion criteria
All children with type 1 diabetes in whom a Medtronic G780 closed-loop pump was placed between November 2020 and March 2022 in our center were included.
Exclusion criteria
Participant opposition
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Glycated hemoglobin | 1 year | Percentage of glycated hemoglobin measured by the MiniMed 780G system |
| Time spent in range Level with glucose levels within the norm | 1 year | Time spent with glucose levels between 70 and 180 mg/dL |
| Time spent with glucose levels below range | 1 year | Time spent with glucose levels inferior to 70mg/dL |
| Time spent with glucose levels above range | 1 year | Time spent with glucose levels superior to 180 mg/dL |
Countries
France
Outcome results
None listed